Enimmune Corporation operates as a biotechnology company specializing in the research, development, production, and marketing of new drugs and vaccines. Its main products include vaccines targeting infectious diseases such as enterovirus 71 (EV71), Japanese encephalitis virus, EV71 plus CA16 bivalent vaccines, pneumococcal vaccines, and biological drugs including monoclonal antibodies. It also develops diagnostic products like the Speedy COVID-19 Ag Rapid Test for SARS-CoV-2 detection. The company undertakes clinical trials, new drug applications, and collaborates with research-based pharmaceutical firms to facilitate drug commercialization. Enimmune’s business model emphasizes strategic alliances within the ecosystem to efficiently bring new drugs to market, including licensing phased results to other manufacturers. Founded in 2014 and headquartered in Taichung City, Taiwan, it is a subsidiary initially established with backing from Adimmune Corporation and venture capital partners. Recent major developments include the launch of the EnVAX-A71 vaccine against enterovirus 71, which received market authorization in Taiwan in early 2023, and ongoing efforts to expand into the ASEAN market through strategic partnerships and clinical trials in Vietnam. Enimmune also secured Halal certification for its vaccine and signed a marketing and sales memorandum of understanding with Vietnam’s largest state-owned vaccine company, targeting protection for children across Asia with annual demand exceeding 20 million doses. The company continues to advance its portfolio with vaccine development for diseases such as norovirus, dengue fever, Middle East respiratory syndrome (MERS), and plans for a Japanese encephalitis vaccine based on cell culture technology, replacing traditional methods. Enimmune’s product offerings extend to biopharmaceutical agents, monoclonal antibodies, small molecule drugs, and innovative diagnostics, positioning it as a key player in Taiwan’s biopharmaceutical industry with a growing international footprint. Its operational strategy leverages high-capacity manufacturing and CDMO services from its parent and associated companies to sustain growth and expand global market reach.